Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$21.89 -10.03%

-$3.24 today

Market cap
$3.71B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 2.75M

Average 3.67M

TNGX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Tango Therapeutics, Inc.NASDAQ: TNGX

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents rises 48.8% from a year ago

Cash & equivalents stood at $86.84M at the end of Q3 FY2026, up 48.8% from a year earlier and down 74.9% from the prior quarter. Over 3 fiscal years it compounded at +23.3% a year.

Context

  • Cash & equivalents amounted to 8.4% of total assets at the end of Q3 FY2026, down 19.4 pp from a year earlier.
  • Cash & equivalents increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +48.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$86.84M-74.9% QoQ
Last fiscal yearDec 2025
$112.28M+61.5% YoY
Year agoSep 2025
$58.34M+48.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.8%——
1 year+61.5%——
3-year CAGR+23.3%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
112.28M USD
Year-over-year change
+61.5%
4-year CAGR
-5.8%

Cash & Equivalents vs competitors

How TNGX compares with its peers on the latest reported figures

  • TNGX's Sep 2026 cash & equivalents of $86.84M is the 8th highest of the 11 companies compared; the peer median is $120.07M.
  • Its year-over-year change of +48.8% is the 4th highest of 11, against a peer median of +20.3%.
  • Cash & equivalents amounts to 8.4% of total assets for TNGX, versus a peer median of 18.7%.
TNGX Competitors Peer median
Cash & Equivalents for TNGX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RVMDRevolution Medicines, Inc.Jun 2026$815.44M +102.6%+33.5%18.9%
NRIXNurix Therapeutics, Inc.Aug 2026$720.24M +818.2%+56.5%60.3%
NUVBNuvation Bio Inc.Jun 2026$258.6M +4.3%+17.5%34.7%
IDYAIDEAYA Biosciences, Inc.Mar 2026$157.52M +21.2%+18.0%15.3%
RLAYRelay Therapeutics, Inc.Jun 2026$121.19M +6.4%-17.9%12.5%
ERASErasca, Inc.Sep 2026$118.96M +69.4%-36.2%11.9%
FHTXFoghorn Therapeutics Inc.Mar 2026$88.91M +45.7%+15.7%40.0%
TNGXTango Therapeutics, Inc.Sep 2026$86.84M +48.8%+23.3%8.4%
CCCCC4 Therapeutics, Inc.Mar 2026$61.27M +19.5%+35.9%18.6%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$34.06M -13.0%+12.0%31.6%
PRLDPrelude Therapeutics IncorporatedMar 2026$21.76M -46.0%+4.8%18.2%
Peer median (excluding TNGX) $120.07M+20.3%+16.6%18.7%

Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents142.75M59.97M66.39M69.53M112.28M
Short-term Investments342.51M306.17M270.5M188.39M230.86M
Net Receivables2M2M000
Inventory00000
Other Current Assets567K7.14M9.65M8.43M10.62M
Total Current Assets492.34M375.27M346.54M266.34M353.76M
Property, Plant & Equipment (Net)6.09M57.77M53.42M47.58M42.49M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.73M3.43M2.61M2.57M2.44M
Total Non-current Assets7.82M61.2M56.03M50.15M44.93M
Total Assets500.16M436.47M402.57M316.49M398.69M
Account Payables3.23M4.45M2.79M1.6M1.18M
Short-term Debt00000
Tax Payables52K35K000
Deferred Revenue26.02M31.79M25.67M17.62M0
Other Current Liabilities666K1.27M7.49M1.74M1.29M
Total Current Liabilities40.69M55.55M45.94M38.17M21.68M
Long-term Debt000030.83M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)114.72M92.09M66.68M44.77M0
Other Non-current Liabilities00000
Total Non-current Liabilities114.72M131.45M103.52M78.81M30.83M
Total Liabilities155.41M186.99M149.46M116.98M52.51M
Common Stock88K88K102K108K136K
Retained Earnings(161.34M)(269.51M)(371.26M)(501.56M)(603.15M)
Accumulated OCI(765K)(3.71M)186K336K224K
Other Stockholders Equity00000
Minority Interest00000
Total Equity344.75M249.48M253.11M199.52M346.18M
Total Debt1.5M41.13M38.92M36.49M33.57M
Net Debt(141.24M)(18.84M)(27.47M)(33.04M)(78.71M)

Tango Therapeutics, Inc.

NASDAQ:TNGX

Intrinsic Alpha fair value

Locked

Current Price

$21.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.